PUBLISHER: The Business Research Company | PRODUCT CODE: 1994643
PUBLISHER: The Business Research Company | PRODUCT CODE: 1994643
The Internet of Medical Things (IoMT) for drug delivery refers to the deployment and integration of connected medical devices, sensors, software, and communication technologies that enable the monitoring, control, and administration of drug delivery through networked systems. It allows precise dosage management, real-time patient monitoring, improved treatment adherence, and enhanced safety tailored to specific therapeutic and clinical requirements.
The primary types of Internet of Medical Things (IoMT) for drug delivery include wearable drug delivery devices, smart inhalers, injectable drug delivery systems, implantable drug delivery devices, and remote drug monitoring solutions. Wearable drug delivery devices are wearable technologies designed to support controlled medication administration while tracking patient adherence and physiological parameters. These products utilize connectivity options such as Bluetooth and low energy (BLE) connectivity, Wi-Fi connectivity, cellular connectivity, near field communication (NFC), and cloud- and edge-based connectivity. They are applied across areas including chronic disease management, acute care drug delivery, home-based medication administration, hospital and clinical drug delivery, and personalized and precision medicine, and are used by end users including hospitals and clinics, home care environments, pharmaceutical and biotechnology companies, research and development organizations, and contract research and clinical trial centers.
Tariffs are impacting the IoMT for drug delivery market by increasing costs of imported sensors, microcontrollers, connectivity modules, embedded software components, and secure cloud infrastructure services. Medical device manufacturers and healthcare providers in North America and Europe are most affected due to reliance on globally sourced electronics, while Asia-Pacific faces cost pressure on device exports. These tariffs are increasing device prices and slowing large-scale deployment. However, they are also encouraging regional electronics manufacturing, localized device assembly, and greater investment in domestic digital health ecosystems.
The internet of medical things (iomt) for drug delivery market research report is one of a series of new reports from The Business Research Company that provides internet of medical things (iomt) for drug delivery market statistics, including internet of medical things (iomt) for drug delivery industry global market size, regional shares, competitors with a internet of medical things (iomt) for drug delivery market share, detailed internet of medical things (iomt) for drug delivery market segments, market trends and opportunities, and any further data you may need to thrive in the internet of medical things (iomt) for drug delivery industry. This internet of medical things (iomt) for drug delivery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The internet of medical things (iomt) for drug delivery market size has grown strongly in recent years. It will grow from $6.57 billion in 2025 to $7.14 billion in 2026 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to increasing prevalence of chronic diseases, early adoption of smart infusion and monitoring devices, growth of home healthcare services, rising focus on medication adherence, expansion of digital health infrastructure.
The internet of medical things (iomt) for drug delivery market size is expected to see strong growth in the next few years. It will grow to $10.09 billion in 2030 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to expansion of personalized medicine applications, rising investments in connected healthcare platforms, growing demand for remote patient management, increasing integration of AI-driven dosing algorithms, rising regulatory support for digital therapeutics. Major trends in the forecast period include increasing adoption of connected drug delivery devices, rising use of real-time patient monitoring platforms, growing integration of wearable and implantable delivery systems, expansion of personalized dosage management solutions, enhanced focus on remote therapy management.
The growing adoption of telehealth and remote care services is expected to drive the expansion of the internet of medical things (IoMT) for drug delivery market in the coming years. Telehealth and remote care services refer to the delivery of healthcare through digital technologies that enable patients to access medical consultations, monitoring, and treatment from their homes without requiring in-person visits. The expansion of telehealth and remote care services is driven by increasing patient demand for convenient, on-demand healthcare that allows individuals to consult physicians, monitor health conditions, and manage treatments from home without frequent hospital visits. The internet of medical things (IoMT) for drug delivery strengthens telehealth and remote care services by enabling real-time monitoring of patient medication adherence, precise and automated drug delivery, and seamless data sharing with healthcare providers, allowing physicians to remotely track treatment progress, adjust dosages, and deliver personalized care without in-person appointments. For instance, in April 2023, according to FAIR Health Inc., a US-based non-profit organization, nationwide telehealth usage rose by 7.3%, increasing from 5.5% of medical claim lines in December 2022 to 5.9% in January 2023. Therefore, the increasing adoption of telemedicine platforms is contributing to the growth of the internet of medical things (IoMT) for drug delivery market.
Leading companies operating in the internet of medical things (IoMT) for drug delivery market are emphasizing the development of innovative solutions such as connected smart drug-delivery devices with real-time monitoring to enable personalized dosing, improve treatment adherence, and enhance patient outcomes. Connected smart drug-delivery devices with real-time monitoring are medical devices that automatically track medication administration and patient-related data and wirelessly transmit this information to applications or healthcare systems, helping optimize dosing, improve adherence, and support timely clinical decision-making. For example, in November 2024, Medtronic plc, an Ireland-based healthcare technology company, launched its Smart MDI system featuring the InPen app with Simplera CGM. The system integrates a smart insulin pen with a disposable, all-in-one CGM to deliver real-time, personalized insulin dosing insights, including detection and correction recommendations for missed or inaccurate mealtime doses. It continuously monitors glucose levels, records insulin delivery, and analyzes patient data through a mobile application to reduce the risk of hyperglycemia and support improved glycemic control. Compared with conventional insulin pens, the solution offers automated data capture, intelligent alerts, and clinical decision support, significantly reducing dosing uncertainty and improving patient outcomes.
In June 2024, Aptar Digital Health LLC, a US-based manufacturing company, entered into a partnership with SHL Medical AG to develop connected drug delivery solutions by integrating digital health platforms with advanced self-injection systems. Through this collaboration, Aptar Digital Health and SHL Medical aim to combine Aptar's digital health platforms and connected device capabilities with SHL Medical's autoinjector and pen injector technologies to deliver integrated, connected drug delivery solutions that improve patient adherence, enhance therapy outcomes, and support pharmaceutical companies with real-world data insights. SHL Medical AG is a Switzerland-based medical device company specializing in the design and manufacturing of advanced self-injection systems for pharmaceutical and biotechnology partners.
Major companies operating in the internet of medical things (iomt) for drug delivery market are Siemens AG, F. Hoffmann-La Roche AG, IBM Corporation, Bayer AG, Oracle Corporation, Abbott Laboratories, Honeywell Life Care Solutions Inc., Medtronic plc, Koninklijke Philips N.V., GE HealthCare Technologies Inc., Becton Dickinson and Company, Cognizant Technology Solutions Corporation, Biogen Inc., Omron Healthcare Co. Ltd., Dexcom Inc., Insulet Corporation, Tandem Diabetes Care Inc., Senseonics Inc., AdhereTech Inc., Adherium Limited
North America was the largest region in the internet of medical things (IOMT) for drug delivery market in 2025. The regions covered in the internet of medical things (iomt) for drug delivery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the internet of medical things (iomt) for drug delivery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The internet of medical things (IoMT) for drug delivery market consists of sales of connected drug delivery devices, smart infusion systems, wearable and implantable drug delivery solutions, remote monitoring software, data management platforms, and secure device orchestration products. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Internet Of Medical Things (IOMT) For Drug Delivery Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses internet of medical things (iomt) for drug delivery market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for internet of medical things (iomt) for drug delivery ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The internet of medical things (iomt) for drug delivery market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.